- Home
- FLC vs CMPX Comparison
FLC vs CMPX Comparison
Compare FLC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- CMPX
- Stock Information
- Founded
- FLC 2003
- CMPX 2014
- Country
- FLC United States
- CMPX United States
- Employees
- FLC N/A
- CMPX N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- FLC Finance
- CMPX Health Care
- Exchange
- FLC Nasdaq
- CMPX Nasdaq
- Market Cap
- FLC 168.0M
- CMPX 217.4M
- IPO Year
- FLC N/A
- CMPX N/A
- Fundamental
- Price
- FLC $16.81
- CMPX $1.50
- Analyst Decision
- FLC
- CMPX Strong Buy
- Analyst Count
- FLC 0
- CMPX 2
- Target Price
- FLC N/A
- CMPX $9.00
- AVG Volume (30 Days)
- FLC 37.8K
- CMPX 381.1K
- Earning Date
- FLC 01-01-0001
- CMPX 11-07-2024
- Dividend Yield
- FLC 6.64%
- CMPX N/A
- EPS Growth
- FLC N/A
- CMPX N/A
- EPS
- FLC N/A
- CMPX N/A
- Revenue
- FLC N/A
- CMPX $850,000.00
- Revenue This Year
- FLC N/A
- CMPX N/A
- Revenue Next Year
- FLC N/A
- CMPX $950.68
- P/E Ratio
- FLC N/A
- CMPX N/A
- Revenue Growth
- FLC N/A
- CMPX N/A
- 52 Week Low
- FLC $12.62
- CMPX $0.77
- 52 Week High
- FLC $15.45
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- FLC 69.25
- CMPX 60.19
- Support Level
- FLC $16.79
- CMPX $1.42
- Resistance Level
- FLC $16.96
- CMPX $1.65
- Average True Range (ATR)
- FLC 0.13
- CMPX 0.13
- MACD
- FLC -0.00
- CMPX 0.02
- Stochastic Oscillator
- FLC 71.15
- CMPX 51.95
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.